Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14333952 | 0.79 | PDGFRB (0.46) | PDGFRBCYP2A6NPC1ARADORA2A | |
| SCHEMBL10168097 | 0.77 | PDGFRB (0.45) | PDGFRBCYP2A6NPC1ARADORA2A | |
| SCHEMBL17983446 | 0.76 | ENPP3 (0.36) | PDGFRBNPC1ADORA2AADORA3ADORA1 | |
| SCHEMBL14511620 | 0.75 | GSK3B (0.53) | NPC1ARKDM4E | |
| SCHEMBL14333881 | 0.74 | CYP2A6 (0.50) | PDGFRBCYP2A6NPC1ADORA2AADORA1 | |
| SCHEMBL10955177 | 0.74 | PDGFRB (0.43) | PDGFRBCYP2A6NPC1KDM4E | |
| SCHEMBL7100910 | 0.73 | GSK3B (0.41) | PDGFRBCYP2A6KDM4ECYP2E1CYP2B6 | |
| SCHEMBL1008901 | 0.72 | MEN1 (0.46) | PDGFRBNPC1ADORA2AADORA3ADORA1 | |
| SCHEMBL8250696 | 0.72 | METAP2 (0.44) | NPC1ADORA3KDM4E | |
| SCHEMBL32662992 | 0.72 | PDGFRB (0.43) | PDGFRBNPC1ADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9024018-B2 | 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use | PHARMINOX LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | US | disclosed |
| EP-0954521-B1 | 4- (THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO MCNEIL PHARM INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6465486-B1 | ALPHA2 ADRENOCEPTOR MODULATORS; HYPERTENSION, GLAUCOMA, SEXUAL DYSFUNCTION, DEPRESSION, ATTENTION DEFICIT HYPERACTIVITY DISORDER, PARKINSONISM, NEED FOR ANESTHESIA, CARDIAC ARRYTHMIA | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6426356-B1 | ANALGESICS; HYPOTENSIVE AGENTS; ANTIDEPRESSANTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-07-30 | — | — | US | disclosed |
| US-20020025974-A1 | BICYCLE THIOPHENES AND THIAZOLES | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-02-28 | — | — | US | disclosed |
| US-6313309-B1 | BENZOTHIOPHENYL-1H-IMIDAZOLE ANALGESICS; HYPOTENSIVE AGENTS, ANTIDEPRESSANTS; SEXUAL, ATTENTION DEFICIT, AND HYPERACTIVE DISORDERS; DELTA-OPIOD RECEPTOR AGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-0889891-B1 | 4-[(THIEN-2-YL)METHYL]IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO MCNEIL PHARM INC (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-0954521-A1 | 4- (THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | Ortho-McNeil Pharmaceutical, Inc. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1999051593-A1 | 4-THIONAPHTHYL-1H-IMIDAZOLES WITH ALPHA-2-ADRENERGIC ACTIVITY | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0889891-A1 | 4-[(THIEN-2-YL)METHYL]IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5750720-A | ALPHA-ADRENORECEPTORS AND CENTRAL NERVOUS SYSTEMS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997035858-A1 | 4-[(THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING α2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997035857-A1 | 4-[(THIEN-2-YL)METHYL]IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| US-5621113-A | ALPHA 2 ADRENOCEPTOR AGONISTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | MKI67, CCNA1, CCNI | PDGFRB 516/4885CYP2A6 733/4885NPC1 496/4885 |
| US-20020025974-A1 | BICYCLE THIOPHENES AND THIAZOLES | ADRB1, ADRA1D, ADRA2C | PDGFRB 2220/4885CYP2A6 537/4885NPC1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.